Immunohistochemical expression of granzyme B and perforin in discoid lupus erythematosus

Ultrastructural Pathology

Volumn 37, Issue 6, 2013, Pages 408-416

  Abdou, Asmaa Gaber ^a   Shoeib, Mohammed ^a   Bakry, Ola Ahmed ^a   El Bality, Heba ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

DLE; Granzyme B; Perforin

Indexed keywords

BIOLOGICAL MARKER; GRANZYME; GZMB PROTEIN, HUMAN; PERFORIN;

ADULT; AGE; ARTICLE; BIOPSY; CASE CONTROL STUDY; DISCOID LUPUS ERYTHEMATOSUS; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SKIN; YOUNG ADULT;

ADULT; AGE FACTORS; BIOLOGICAL MARKERS; BIOPSY; CASE-CONTROL STUDIES; FEMALE; GRANZYMES; HUMANS; IMMUNOHISTOCHEMISTRY; LUPUS ERYTHEMATOSUS, DISCOID; MALE; MIDDLE AGED; PERFORIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SKIN; YOUNG ADULT;

EID: 84887938769     PISSN: 01913123     EISSN: 15210758     Source Type: Journal    
DOI: 10.3109/01913123.2013.816400     Document Type: Article

References (26)

1. Vera-Recabarren MA, García-Carrasco M, Ramos-Casals M, Herrero C. Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients. Br J Dermatol 2010;162: 91-101.
2. Callen JP. Cutaneous lupus erythematosus: a personal approach to management. Australas J Dermatol 2006;47: 13-27.
3. Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus 2010;19: 1050-70.
4. Rowell NR, Goodfield MJD. The connective tissue diseases. In: Champion RH, Burton JL, Ebling FJG, eds. Textbook of Dermatology, 5th ed. Oxford, UK: Blackwell Scientific, 1992: 2163-225.
5. Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population- based study. Arch Dermatol 2009;145: 249-53.
6. Boivin WA, Cooper DM, Hiebert PR, Granville DJ. Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab Invest 2009;89: 1195-220.
7. Shah D, Kiran R, Wanchu A, Bhatnagar A. Soluble granzyme B and cytotoxic T lymphocyte activity in the pathogenesis of systemic lupus erythematosus. Cell Immunol 2011;269: 16-21.
8. Bolitho P, Voskoboinik I, Trapani JA, Smyth MJ. Apoptosis induced by the lymphocyte effector molecule perforin. Curr Opin Immunol 2007;19: 339-47.
9. Voskoboinik I, Thia MC, Fletcher J, et al. Calciumdependent plasma membrane binding and cell lysis by perforin are mediated through its C2 domain: a critical role for aspartate residues 429, 435, 483, and 485 but not 491. J Biol Chem 2005;280: 8426-34.
10. Kaiserman D, Buckle AM, Van Damme P, et al. Structure of granzyme C reveals an unusual mechanism of protease autoinhibition. Proc Natl Acad Sci U S A 2009;106: 5587-92.
11. Ammar M, Mokni M, Boubaker S, et al. Involvement of granzyme B and granulysin in the cytotoxic response in lichen planus. J Cutan Pathol 2008;35: 630-4.
12. Lage D, Pimentel VN, Soares TC, et al. Perforin and granzyme B expression in oral and cutaneous lichen planus-a comparative study. J Cutan Pathol 2011;38: 973-8.
13. Yawalkar N, Hunger RE, Buri C, et al. A comparative study of the expression of cytotoxic proteins in allergic contact dermatitis and psoriasis: spongiotic skin lesions in allergic contact dermatitis are highly infiltrated by T cells expressing perforin and granzyme B. Am J Pathol 2001;158: 803-8.
14. Batinac T, Zamolo G, Coklo M, Hadzisejdic I. Possible key role of granzyme B in keratoacanthoma regression. Med Hypotheses 2006;66: 1129-32.
15. Malyguine AM, Strobl S, Dunham K, et al. ELISPOT assay for monitoring cytotoxic T lymphocytes (CTL) activity in cancer vaccine clinical trials. Cells 2012;1: 111-26.
16. Thiery J, Keefe D, Boulant S, et al. Perforin pores in the endosomal membrane trigger release of endocytosed granzyme B to the cytosol of target cells. Nat Immunol 2011;12: 770-77.
17. Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ 2010;17: 616-23.
18. Grassi M, Capello F, Bertolino L, et al. Identification of granzyme B-expressing CD-8-positive T cells in lymphocytic inflammatory infiltrate in cutaneous lupus erythematosus and in dermatomyositis. Clin Exp Dermatol 2009;34: 910-14.
19. Wenzel J, Uerlich M, Worrenkamper E, et al. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferoninduced protein MxA. Br J Dermatol 2005;153: 1011-15.
20. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002;20: 323-70.
21. Herzinger T, Plewig G, Rocken M. Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum 2004;50: 3045-6.
22. Millard TP, Hawk JL, McGregor JM. Photosensitivity in lupus. Lupus 2000;9: 3-10.
23. Meller S, Winterberg F, Gilliet M, et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment, an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005;52: 1504-6.
24. Smyth MJ, Cretney E, Takeda K, et al. Tumor-necrosis factor-related apoptosis inducing ligand (TRAIL) contributes to interferon dependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193: 661-70.
25. Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 2003;3: 361-70.
26. Pipkin ME, Lieberman J. Delivering the kiss of death: progress on understanding how perforin works. Curr Opin Immunol 2007;19: 301-8.